<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29869" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tamoxifen</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Farrar</surname>
            <given-names>Maela C.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jacobs</surname>
            <given-names>Tibb F.</given-names>
          </name>
          <aff>University of Louisiana Monroe</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maela Farrar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tibb Jacobs declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29869.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Tamoxifen is indicated for the treatment of breast cancer in a variety of settings. It should be noted that evidence suggests that patients with estrogen receptor-positive tumors are more likely to benefit from tamoxifen. FDA-approved Indications include treatment of breast cancer in both females and males, adjuvant treatment of breast cancer after patients have completed their primary treatment with surgery and radiation, treatment of female patients with ductal carcinoma in situ (non-invasive breast cancer) after surgery, and radiation to reduce the risk of invasive breast cancer, and breast cancer risk reduction in certain patients at high risk. Tamoxifen also has many off-labeled uses, and they may require additional data. This activity outlines the indications, mechanism of action, methods of administration, important adverse effects, contraindications, toxicity, and monitoring, of tamoxifen, so providers can direct patient therapy in treating indicated disorders as part of the interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the mechanism of action of tamoxifen.</p></list-item><list-item><p>Identify the approved indications of tamoxifen, and cite some of the non-approved indications as well.</p></list-item><list-item><p>Review the adverse event profile of tamoxifen therapy.</p></list-item><list-item><p>Describe interprofessional team strategies for improving care coordination and communication to properly use tamoxifen to improve patient outcomes in the varied scenarios where it can be effective.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29869&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29869">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29869.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Tamoxifen is a selective estrogen receptor modulator (SERM) medication used to treat breast cancer in men and women and as a prophylactic agent against breast cancer in women. The drug was first synthesized in 1962 and initially intended to be a birth control drug, but while it failed&#x000a0;for that indication, it has become a very successful anti-cancer medication.<xref ref-type="bibr" rid="article-29869.r1">[1]</xref> Specifically, it is indicated for the treatment of breast cancer in a variety of settings. It should be noted that evidence suggests that patients with estrogen receptor-positive tumors are more likely to benefit from tamoxifen.<xref ref-type="bibr" rid="article-29869.r2">[2]</xref> Tamoxifen also has many off-labeled uses and may require additional data.&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment of breast cancer in both females and males<xref ref-type="bibr" rid="article-29869.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Adjuvant treatment of breast cancer after patients have completed their primary treatment with surgery and radiation<xref ref-type="bibr" rid="article-29869.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of female patients with ductal carcinoma in situ (non-invasive breast cancer) after surgery and radiation to reduce the risk of invasive breast cancer<xref ref-type="bibr" rid="article-29869.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Breast cancer risk reduction in certain patients at high risk (5-year risk = 1.67% calculated by the Gail Model).<xref ref-type="bibr" rid="article-29869.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Non-FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment of progressive or recurrent desmoid tumors in combination with sulindac<xref ref-type="bibr" rid="article-29869.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of endometrioid histologies that are recurrent, metastatic, or at high-risk<xref ref-type="bibr" rid="article-29869.r8">[8]</xref><xref ref-type="bibr" rid="article-29869.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of primary or secondary gynecomastia along with breast pain associated with it<xref ref-type="bibr" rid="article-29869.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Induction of ovulation in the treatment of infertility<xref ref-type="bibr" rid="article-29869.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of oligospermia in combination with testosterone<xref ref-type="bibr" rid="article-29869.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Prophylaxis of coronary arteriosclerosis in men with a triple vessel<xref ref-type="bibr" rid="article-29869.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of advanced or recurrent ovarian cancer<xref ref-type="bibr" rid="article-29869.r14">[14]</xref><xref ref-type="bibr" rid="article-29869.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of bladder cancer<xref ref-type="bibr" rid="article-29869.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of lung cancer in addition to initial chemotherapy treatment<xref ref-type="bibr" rid="article-29869.r17">[17]</xref><xref ref-type="bibr" rid="article-29869.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of precocious puberty due to McCune-Albright syndrome in females<xref ref-type="bibr" rid="article-29869.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of metastatic malignant melanoma in combination with other agents&#x000a0;including carmustine, cisplatin, and dacarbazine<xref ref-type="bibr" rid="article-29869.r20">[20]</xref><xref ref-type="bibr" rid="article-29869.r21">[21]</xref><xref ref-type="bibr" rid="article-29869.r22">[22]</xref><xref ref-type="bibr" rid="article-29869.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of benign mammary dysplasia<xref ref-type="bibr" rid="article-29869.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of bone metastasis<xref ref-type="bibr" rid="article-29869.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of carcinoid tumor&#x000a0;<xref ref-type="bibr" rid="article-29869.r26">[26]</xref>,&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Treatment of cutaneous polyarteritis nodosa<xref ref-type="bibr" rid="article-29869.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of hypertrophy of the uterus<xref ref-type="bibr" rid="article-29869.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of meningioma<xref ref-type="bibr" rid="article-29869.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of primary breast pain, premenstrual mastodynia, or breast pain that originated from liver cirrhosis<xref ref-type="bibr" rid="article-29869.r30">[30]</xref><xref ref-type="bibr" rid="article-29869.r31">[31]</xref><xref ref-type="bibr" rid="article-29869.r32">[32]</xref><xref ref-type="bibr" rid="article-29869.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Prophylaxis of postmenopausal osteoporosis<xref ref-type="bibr" rid="article-29869.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p>Improvement of length and quality of life in patients with retinoblastoma in addition to treatment protocols<xref ref-type="bibr" rid="article-29869.r35">[35]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of Riedel thyroiditis<xref ref-type="bibr" rid="article-29869.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of solid tumor secondary malignant neoplasms<xref ref-type="bibr" rid="article-29869.r37">[37]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29869.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Tamoxifen exhibits both estrogenic agonist and antagonist effects in different parts of the body. It selectively binds to estrogen receptors, producing both estrogenic and anti-estrogen effects; because it has two actions, it is patient-specific as a selective estrogen receptor modulator (SERM).</p>
        <p>In the breast tissue, it antagonistically competes with estrogen for binding sites and causes antiestrogenic and antitumor effects. It slows cell cycling through downstream intracellular processes, which&#x000a0;classifies it as cytostatic. In bone, it stimulates estrogen receptors instead of blocking them, exerting an estrogenic agonist effect, and may prevent osteoporosis in postmenopausal women.<xref ref-type="bibr" rid="article-29869.r38">[38]</xref>&#x000a0;It also acts as an estrogen agonist in the hypothalamus of premenopausal women, which increases gonadotropin levels and can induce ovulation. In McCune-Albright syndrome, its mechanism of action remains unknown.<xref ref-type="bibr" rid="article-29869.r39">[39]</xref></p>
        <p>Tamoxifen is metabolized hepatically via the CYP450 enzyme system; specifically, it is a 2B6, 2C9, 2C19, 2D6, and 3A4 substrate. Its half-life is between 5 and 7 days as tamoxifen and 14 days as its active metabolite N-desmethyl-tamoxifen. It is primarily excreted in the feces.<xref ref-type="bibr" rid="article-29869.r40">[40]</xref></p>
      </sec>
      <sec id="article-29869.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Tamoxifen is available in a tablet (10 mg or 20 mg) or an oral solution (10 mg/5 mL). If administered as an oral solution, it is important to use the supplied dosing cup for adequate administration.</p>
        <p>FDA-approved indication dosing is as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>The American Society of Clinical Oncology (ASCO) guidelines for Adjuvant Endocrine Therapy of Hormone-Receptor Positive Breast Cancer recommends a dose of 20 mg daily for breast cancer prevention after completion of chemotherapy. The duration of endocrine therapy depends on the patient's menopausal status and can last 5 to 10 years.<xref ref-type="bibr" rid="article-29869.r41">[41]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>To treat metastatic breast cancer, 20 to 40 mg daily is recommended, although clinical benefit has not been shown for doses above 20 mg daily.<xref ref-type="bibr" rid="article-29869.r42">[42]</xref> In some&#x000a0;off-label clinical trials, 10 mg was used as the dose.&#x000a0;Patients may&#x000a0;take the drug without regard to food.</p>
          </list-item>
          <list-item>
            <p>Breast cancer prophylaxis dosing is 20 mg daily for five years; used on high-risk females.</p>
          </list-item>
          <list-item>
            <p>For ductal cancer in situ (DCIS), dosing is 20 mg daily by mouth for five years following breast cancer surgery and X-ray therapy to decrease the risk of invasive breast cancer.<xref ref-type="bibr" rid="article-29869.r43">[43]</xref></p>
          </list-item>
        </list>
        <p>Off-label dosing for some indications is:</p>
        <list list-type="bullet">
          <list-item>
            <p>Mastalgia: 10 mg orally once daily for four months.</p>
          </list-item>
          <list-item>
            <p>Ovulation induction:&#x000a0; 5 to 40 mg by mouth once daily for four days.</p>
          </list-item>
          <list-item>
            <p>Precocious puberty (ages 2 to 10): 20 mg orally daily for female patients with McCune-Albright syndrome.<xref ref-type="bibr" rid="article-29869.r19">[19]</xref><xref ref-type="bibr" rid="article-29869.r39">[39]</xref></p>
          </list-item>
        </list>
        <p>There are no necessary dose adjustments in patients with renal impairment. Hepatic dosing remains undefined as of this writing.</p>
      </sec>
      <sec id="article-29869.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Tamoxifen has a black box warning for uterine malignancies, pulmonary embolism, and stroke in patients who&#x000a0;are at high risk for cancer or who have ductal carcinoma in situ.<xref ref-type="bibr" rid="article-29869.r44">[44]</xref> In patients who are female, tamoxifen is associated with an increased incidence of uterine or endometrial cancers, with some being fatal. In patients who were already diagnosed with breast cancer, however, the benefits outweigh the risks.<xref ref-type="bibr" rid="article-29869.r45">[45]</xref></p>
        <p>Like many cancer drugs, tamoxifen has many adverse effects associated with it, though serious and fatal ones are rare. The most common adverse effects seen in treatment are hot flashes, irregular periods, and vaginal discharge. Other common adverse effects include peripheral edema, hypertension, mood changes, pain, depression, skin changes and skin rashes, nausea and vomiting, weakness, arthritis, arthralgia, lymphedema, and pharyngitis.</p>
        <p>Less common adverse effects may include insomnia, dizziness, headache, weight gain, abdominal pain, diarrhea, indigestion, urinary tract infections, thrombocytopenia, back pain, alopecia, ostealgia, and cataracts among many more. Due to the extensive adverse effects of tamoxifen, it is important for patients to discuss all adverse effects they are experiencing with their doctor.<xref ref-type="bibr" rid="article-29869.r46">[46]</xref></p>
        <p>Tamoxifen can also cause a local disease flare which may lead to increased bone and tumor pain. This can be associated with good tumor response and usually resolves quickly. In patients with bone metastasis, hypercalcemia may occur. If hypercalcemia becomes severe and not manageable, discontinue tamoxifen.<xref ref-type="bibr" rid="article-29869.r47">[47]</xref></p>
      </sec>
      <sec id="article-29869.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Tamoxifen should not be used in patients with a known allergy to&#x000a0;the drug or any component in its formulation or concomitantly with warfarin. For patients taking tamoxifen for breast cancer risk reduction at high risk for breast cancer or ductal carcinoma in situ, it should be avoided if the patient has a history of deep vein thrombosis (DVT) or pulmonary embolism (PE). In patients that have been diagnosed with breast cancer, the benefits outweigh the risks,&#x000a0;but it should still be used with caution in patients with a history of thromboembolic events.</p>
        <p>Caution is recommended in patients who are poor CYP2C9 metabolizers.<xref ref-type="bibr" rid="article-29869.r48">[48]</xref></p>
        <p>Tamoxifen also has many drug-drug interactions, so a comprehensive medication list is crucial for all patients receiving it.<xref ref-type="bibr" rid="article-29869.r49">[49]</xref>&#x000a0;As mentioned above, it is contraindicated for concurrent use with warfarin.</p>
        <p>Tamoxifen use should be avoided in pregnancy; based on limited human data, the risk of teratogenicity and fetal harm exists.&#x000a0;Women should avoid breastfeeding during treatment and for three months following discontinuing therapy due to the risk of infant harm. Tamoxifen also reduces milk production, particularly during the early post-partum period.<xref ref-type="bibr" rid="article-29869.r50">[50]</xref></p>
      </sec>
      <sec id="article-29869.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>All patients on tamoxifen should have routine lab work, including a complete blood count with platelets, serum calcium, and liver function tests. Female patients should monitor for abnormal vaginal bleeding and receive a breast and gynecologic exam at baseline and routinely after. Patients should also watch for signs and symptoms of a DVT or PE.</p>
        <p>Other monitoring parameters tend to&#x000a0;vary depending on patient-specific factors. In patients with pre-existing hyperlipidemia, triglycerides and cholesterol should require monitoring.<xref ref-type="bibr" rid="article-29869.r51">[51]</xref> Patients on vitamin K antagonists should have their INR and PT checked.<xref ref-type="bibr" rid="article-29869.r52">[52]</xref> Reproductive female patients need a pregnancy test before treatment and should use reliable birth control methods during treatment.<xref ref-type="bibr" rid="article-29869.r53">[53]</xref> Premenopausal women should receive a bone mineral density test. All patients should get an ophthalmic exam if vision problems or cataracts occur.<xref ref-type="bibr" rid="article-29869.r54">[54]</xref></p>
      </sec>
      <sec id="article-29869.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There is currently&#x000a0;no antidote available for tamoxifen.</p>
      </sec>
      <sec id="article-29869.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Interprofessional teamwork and communication provide increased odds of success for all patients, especially those undergoing cancer treatments. Oncologists should thoroughly&#x000a0;evaluate the patient and select an appropriate treatment regimen based on guidelines and patient-specific factors. For example, in estrogen receptor-negative breast cancer, tamoxifen may not be appropriate. This is where the services and input of an oncology-specialized pharmacist can prove invaluable. Other clinicians, including mid-level practitioners, who treat the patient need to be made aware of the patient's tamoxifen therapy, so they can factor that into their own treatment regimens for other conditions and be alert to potential adverse events or treatment failure,</p>
        <p>Oncology nurses should be aware of the more severe adverse effects tamoxifen may cause and look out for them in their patients, reporting concerns to the interprofessional clinical team. Pharmacists should assist the clinical team by examining the patient&#x02019;s current and complete drug regimen and ensuring no interactions exist with their other medications, as tamoxifen has many. All interprofessional team members need to provide patient counseling and answer patient questions since an informed patient will be more compliant and be able to self-report potential issues as they arise. These are just a few examples, and roles tend to&#x000a0;overlap in many different professions, but every healthcare professional provides a vital role that, in turn, benefits the patient greatly through improved therapeutic outcomes and minimizing of adverse events. [Level 5]</p>
      </sec>
      <sec id="article-29869.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29869&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29869">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29869/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29869">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29869.s11">
        <title>References</title>
        <ref id="article-29869.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quirke</surname>
                <given-names>VM</given-names>
              </name>
            </person-group>
            <article-title>Tamoxifen from Failed Contraceptive Pill to Best-Selling Breast Cancer Medicine: A Case-Study in Pharmaceutical Innovation.</article-title>
            <source>Front Pharmacol</source>
            <year>2017</year>
            <volume>8</volume>
            <fpage>620</fpage>
            <pub-id pub-id-type="pmid">28955226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brufsky</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Dickler</surname>
                <given-names>MN</given-names>
              </name>
            </person-group>
            <article-title>Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.</article-title>
            <source>Oncologist</source>
            <year>2018</year>
            <month>May</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>528</fpage>
            <page-range>528-539</page-range>
            <pub-id pub-id-type="pmid">29352052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eggemann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Altmann</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Ignatov</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer.</article-title>
            <source>J Cancer Res Clin Oncol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>144</volume>
            <issue>2</issue>
            <fpage>337</fpage>
            <page-range>337-341</page-range>
            <pub-id pub-id-type="pmid">29098396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gradishar</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Salerno</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>NCCN Guidelines Update: Breast Cancer.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2016</year>
            <month>May</month>
            <volume>14</volume>
            <issue>5 Suppl</issue>
            <fpage>641</fpage>
            <page-range>641-4</page-range>
            <pub-id pub-id-type="pmid">27226503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Staley</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McCallum</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bruce</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis.</article-title>
            <source>Breast</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>546</fpage>
            <page-range>546-51</page-range>
            <pub-id pub-id-type="pmid">25023044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sauter</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Breast Cancer Prevention: Current Approaches and Future Directions.</article-title>
            <source>Eur J Breast Health</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>64</fpage>
            <page-range>64-71</page-range>
            <pub-id pub-id-type="pmid">29774312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hansmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Adolph</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vogel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moeslein</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors.</article-title>
            <source>Cancer</source>
            <year>2004</year>
            <month>Feb</month>
            <day>01</day>
            <volume>100</volume>
            <issue>3</issue>
            <fpage>612</fpage>
            <page-range>612-20</page-range>
            <pub-id pub-id-type="pmid">14745880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thigpen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Homesley</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Soper</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.</article-title>
            <source>J Clin Oncol</source>
            <year>2001</year>
            <month>Jan</month>
            <day>15</day>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>364</fpage>
            <page-range>364-7</page-range>
            <pub-id pub-id-type="pmid">11208827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiorica</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Brunetto</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Hanjani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lentz</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Mannel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>W</given-names>
              </name>
              <collab>Gynecologic Oncology Group study</collab>
            </person-group>
            <article-title>Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.</article-title>
            <source>Gynecol Oncol</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>92</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-4</page-range>
            <pub-id pub-id-type="pmid">14751131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boccardo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rubagotti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Battaglia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Tonno</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Selvaggi</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Comeri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bertaccini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martorana</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Galassi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zattoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Macchiarella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Siragusa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Muscas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Durand</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Potenzoni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Manganelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferraris</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Montefiore</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>Feb</month>
            <day>01</day>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>808</fpage>
            <page-range>808-15</page-range>
            <pub-id pub-id-type="pmid">15681525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steiner</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Terplan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paulson</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis.</article-title>
            <source>Hum Reprod</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>1511</fpage>
            <page-range>1511-5</page-range>
            <pub-id pub-id-type="pmid">15845599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adamopoulos</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Pappa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Billa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nicopoulou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koukkou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Michopoulos</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia.</article-title>
            <source>Fertil Steril</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>80</volume>
            <issue>4</issue>
            <fpage>914</fpage>
            <page-range>914-20</page-range>
            <pub-id pub-id-type="pmid">14556812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clarke</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Schofield</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Grace</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Metcalfe</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kirschenlohr</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis.</article-title>
            <source>Circulation</source>
            <year>2001</year>
            <month>Mar</month>
            <day>20</day>
            <volume>103</volume>
            <issue>11</issue>
            <fpage>1497</fpage>
            <page-range>1497-502</page-range>
            <pub-id pub-id-type="pmid">11257075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatch</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Beecham</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Blessing</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Creasman</surname>
                <given-names>WT</given-names>
              </name>
            </person-group>
            <article-title>Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients.</article-title>
            <source>Cancer</source>
            <year>1991</year>
            <month>Jul</month>
            <day>15</day>
            <volume>68</volume>
            <issue>2</issue>
            <fpage>269</fpage>
            <page-range>269-71</page-range>
            <pub-id pub-id-type="pmid">2070324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iseminger</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Hatch</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Creasman</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dubeshter</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report.</article-title>
            <source>Gynecol Oncol</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>62</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-6</page-range>
            <pub-id pub-id-type="pmid">8690289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dellagrammaticas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bryden</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>GN</given-names>
              </name>
            </person-group>
            <article-title>Regression of metastatic transitional cell carcinoma in response to tamoxifen.</article-title>
            <source>J Urol</source>
            <year>2001</year>
            <month>May</month>
            <volume>165</volume>
            <issue>5</issue>
            <fpage>1631</fpage>
            <pub-id pub-id-type="pmid">11342939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma.</article-title>
            <source>Cancer</source>
            <year>1999</year>
            <month>Aug</month>
            <day>01</day>
            <volume>86</volume>
            <issue>3</issue>
            <fpage>415</fpage>
            <page-range>415-20</page-range>
            <pub-id pub-id-type="pmid">10430249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Figueredo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goodyear</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Findlay</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Neville</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Normandeau</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer. A phase I/II study.</article-title>
            <source>Cancer</source>
            <year>1990</year>
            <month>May</month>
            <day>01</day>
            <volume>65</volume>
            <issue>9</issue>
            <fpage>1895</fpage>
            <page-range>1895-902</page-range>
            <pub-id pub-id-type="pmid">2164872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eugster</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Reiter</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Plourde</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jou</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Pescovitz</surname>
                <given-names>OH</given-names>
              </name>
              <collab>McCune-Albright Study Group</collab>
            </person-group>
            <article-title>Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial.</article-title>
            <source>J Pediatr</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>143</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-6</page-range>
            <pub-id pub-id-type="pmid">12915825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beguerie</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Xingzhong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Valdez</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Tamoxifen vs. non-tamoxifen treatment for advanced melanoma: a meta-analysis.</article-title>
            <source>Int J Dermatol</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>49</volume>
            <issue>10</issue>
            <fpage>1194</fpage>
            <page-range>1194-202</page-range>
            <pub-id pub-id-type="pmid">20883410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Day</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Boasberg</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Kristedja</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Fournier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cabot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>DeGregorio</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Gammon</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma.</article-title>
            <source>Cancer</source>
            <year>2001</year>
            <month>Aug</month>
            <day>01</day>
            <volume>92</volume>
            <issue>3</issue>
            <fpage>609</fpage>
            <page-range>609-19</page-range>
            <pub-id pub-id-type="pmid">11505406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McClay</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>McClay</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Monroe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Metcalf</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Maize</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.</article-title>
            <source>Br J Cancer</source>
            <year>2000</year>
            <month>Jul</month>
            <volume>83</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <page-range>16-21</page-range>
            <pub-id pub-id-type="pmid">10883662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKeage</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lorentzos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gore</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Tamoxifen and chemotherapy for refractory metastatic malignant melanoma.</article-title>
            <source>N Engl J Med</source>
            <year>1993</year>
            <month>Jan</month>
            <day>14</day>
            <volume>328</volume>
            <issue>2</issue>
            <fpage>140</fpage>
            <page-range>140-1</page-range>
            <pub-id pub-id-type="pmid">8416433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ricciardi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ianniruberto</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Tamoxifen-induced regression of benign breast lesions.</article-title>
            <source>Obstet Gynecol</source>
            <year>1979</year>
            <month>Jul</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>80</fpage>
            <page-range>80-4</page-range>
            <pub-id pub-id-type="pmid">377165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taetle</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mendelsohn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Hypercalcemia and tamoxifen readministered.</article-title>
            <source>Ann Intern Med</source>
            <year>1978</year>
            <month>Aug</month>
            <volume>89</volume>
            <issue>2</issue>
            <fpage>287</fpage>
            <pub-id pub-id-type="pmid">677600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moertel</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Engstrom</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Schutt</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Tamoxifen therapy for metastatic carcinoid tumor: a negative study.</article-title>
            <source>Ann Intern Med</source>
            <year>1984</year>
            <month>Apr</month>
            <volume>100</volume>
            <issue>4</issue>
            <fpage>531</fpage>
            <page-range>531-2</page-range>
            <pub-id pub-id-type="pmid">6200021</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cvancara</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Meffert</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Elston</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Estrogen-sensitive cutaneous polyarteritis nodosa: response to tamoxifen.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1998</year>
            <month>Oct</month>
            <volume>39</volume>
            <issue>4 Pt 1</issue>
            <fpage>643</fpage>
            <page-range>643-6</page-range>
            <pub-id pub-id-type="pmid">9777776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fraser</surname>
                <given-names>IS</given-names>
              </name>
            </person-group>
            <article-title>Menorrhagia due to myometrial hypertrophy: treatment with tamoxifen.</article-title>
            <source>Obstet Gynecol</source>
            <year>1987</year>
            <month>Sep</month>
            <volume>70</volume>
            <issue>3 Pt 2</issue>
            <fpage>505</fpage>
            <page-range>505-6</page-range>
            <pub-id pub-id-type="pmid">3627613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markwalder</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Seiler</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Zava</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Antiestrogenic therapy of meningiomas--a pilot study.</article-title>
            <source>Surg Neurol</source>
            <year>1985</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>245</fpage>
            <page-range>245-9</page-range>
            <pub-id pub-id-type="pmid">4023903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Serels</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Melman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Tamoxifen as treatment for gynecomastia and mastodynia resulting from hormonal deprivation.</article-title>
            <source>J Urol</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>159</volume>
            <issue>4</issue>
            <fpage>1309</fpage>
            <pub-id pub-id-type="pmid">9507867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fentiman</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Caleffi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hamed</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chaudary</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial.</article-title>
            <source>Br J Surg</source>
            <year>1988</year>
            <month>Sep</month>
            <volume>75</volume>
            <issue>9</issue>
            <fpage>845</fpage>
            <page-range>845-6</page-range>
            <pub-id pub-id-type="pmid">3052691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cellura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Geranio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Porpiglia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Piacentino</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>[Clinical efficacy of tamoxifen in the treatment of premenstrual mastodynia].</article-title>
            <source>Minerva Ginecol</source>
            <year>1998</year>
            <month>Mar</month>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>101</fpage>
            <page-range>101-3</page-range>
            <pub-id pub-id-type="pmid">9595924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>FY</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>FY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>95</volume>
            <issue>4</issue>
            <fpage>1051</fpage>
            <page-range>1051-5</page-range>
            <pub-id pub-id-type="pmid">10763958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kristensen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ejlertsen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dalgaard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Holmegaard</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Transb&#x000f8;l</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mouridsen</surname>
                <given-names>HT</given-names>
              </name>
            </person-group>
            <article-title>Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study.</article-title>
            <source>J Clin Oncol</source>
            <year>1994</year>
            <month>May</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>992</fpage>
            <page-range>992-7</page-range>
            <pub-id pub-id-type="pmid">8164053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ta&#x000e7;yildiz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yavuz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Unal</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>G&#x000fc;nd&#x000fc;z</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>G&#x000fc;nalp</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ekinci</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Encouraging result of tamoxifen in a retinoblastoma patient with central nervous system metastasis.</article-title>
            <source>Pediatr Hematol Oncol</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>473</fpage>
            <page-range>473-6</page-range>
            <pub-id pub-id-type="pmid">14631622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jaap</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dempster</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Tamoxifen therapy in steroid resistant Reidel's thyroiditis.</article-title>
            <source>Scott Med J</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>46</volume>
            <issue>2</issue>
            <fpage>56</fpage>
            <page-range>56-7</page-range>
            <pub-id pub-id-type="pmid">11394342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lissoni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Paolorossi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tancini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ardizzoia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brivio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Maestroni</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Chilelli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients.</article-title>
            <source>Br J Cancer</source>
            <year>1996</year>
            <month>Nov</month>
            <volume>74</volume>
            <issue>9</issue>
            <fpage>1466</fpage>
            <page-range>1466-8</page-range>
            <pub-id pub-id-type="pmid">8912546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.</article-title>
            <source>Taiwan J Obstet Gynecol</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-31</page-range>
            <pub-id pub-id-type="pmid">18400579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neyman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eugster</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Girls and Boys with McCune-Albright Syndrome with Precocious Puberty - Update 2017.</article-title>
            <source>Pediatr Endocrinol Rev</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>136</fpage>
            <page-range>136-141</page-range>
            <pub-id pub-id-type="pmid">29292624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taniguchi-Takizawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kume</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamazaki</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Different substrate elimination rates of model drugs pH-dependently mediated by flavin-containing monooxygenases and cytochromes P450 in human liver microsomes.</article-title>
            <source>Drug Metab Pharmacokinet</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>40</volume>
            <fpage>100412</fpage>
            <pub-id pub-id-type="pmid">34352706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burstein</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Temin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Buchholz</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Gelmon</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Giordano</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Hudis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Rowden</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Solky</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Stearns</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Winer</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Griggs</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Jul</month>
            <day>20</day>
            <volume>32</volume>
            <issue>21</issue>
            <fpage>2255</fpage>
            <page-range>2255-69</page-range>
            <pub-id pub-id-type="pmid">24868023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bratherton</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Buchanan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kingsley Pillers</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.</article-title>
            <source>Br J Cancer</source>
            <year>1984</year>
            <month>Aug</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>199</fpage>
            <page-range>199-205</page-range>
            <pub-id pub-id-type="pmid">6380554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buttiron Webber</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Puntoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giuliano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Briata</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Cevasco</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Clavarezza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Amico</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Defferrari</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gozza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Provinciali</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lazzeroni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bonanni</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>DeCensi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Patient- versus physician-reported outcomes in a low-dose tamoxifen trial in noninvasive breast cancer.</article-title>
            <source>Breast J</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>11</issue>
            <fpage>817</fpage>
            <page-range>817-823</page-range>
            <pub-id pub-id-type="pmid">34626060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hernandez</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>S&#x000f8;rensen</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lash</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study.</article-title>
            <source>Cancer</source>
            <year>2009</year>
            <month>Oct</month>
            <day>01</day>
            <volume>115</volume>
            <issue>19</issue>
            <fpage>4442</fpage>
            <page-range>4442-9</page-range>
            <pub-id pub-id-type="pmid">19569248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fisher</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Costantino</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Redmond</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Wickerham</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Cronin</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>1994</year>
            <month>Apr</month>
            <day>06</day>
            <volume>86</volume>
            <issue>7</issue>
            <fpage>527</fpage>
            <page-range>527-37</page-range>
            <pub-id pub-id-type="pmid">8133536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nowsheen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aziz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Georgakilas</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs.</article-title>
            <source>Pharmacol Ther</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>139</volume>
            <issue>3</issue>
            <fpage>392</fpage>
            <page-range>392-404</page-range>
            <pub-id pub-id-type="pmid">23711794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulvenna</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Podd</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Life-threatening tamoxifen-induced hypercalcaemia.</article-title>
            <source>Clin Oncol (R Coll Radiol)</source>
            <year>1999</year>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>193</fpage>
            <page-range>193-5</page-range>
            <pub-id pub-id-type="pmid">10465476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manish</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lynn</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cytochrome P450 2C9 polymorphism: Effect of amino acid substitutions on protein flexibility in the presence of tamoxifen.</article-title>
            <source>Comput Biol Chem</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>84</volume>
            <fpage>107166</fpage>
            <pub-id pub-id-type="pmid">31785970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antunes</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Timm</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>de Oliveira</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Staudt</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Raymundo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>G&#x000f6;ssling</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Biaz&#x000fa;s</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Cavalheiro</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rosa</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Wallemacq</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Haufroid</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Linden</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schwartsmann</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation.</article-title>
            <source>Ther Drug Monit</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>6</issue>
            <fpage>733</fpage>
            <page-range>733-44</page-range>
            <pub-id pub-id-type="pmid">25853922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r50">
          <label>50</label>
          <element-citation publication-type="book">
            <chapter-title>Tamoxifen</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kandasamy</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Dharanipragada</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Tamoxifen-induced hypertriglyceridemia causing acute pancreatitis.</article-title>
            <source>J Pharmacol Pharmacother</source>
            <year>2016</year>
            <season>Jan-Mar</season>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-40</page-range>
            <pub-id pub-id-type="pmid">27127396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Givens</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Bullock</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Franks</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Safety of concomitant tamoxifen and warfarin.</article-title>
            <source>Ann Pharmacother</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>43</volume>
            <issue>11</issue>
            <fpage>1867</fpage>
            <page-range>1867-71</page-range>
            <pub-id pub-id-type="pmid">19843839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barthelmes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gateley</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Tamoxifen and pregnancy.</article-title>
            <source>Breast</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>446</fpage>
            <page-range>446-51</page-range>
            <pub-id pub-id-type="pmid">15563850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29869.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paganini-Hill</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Eye problems in breast cancer patients treated with tamoxifen.</article-title>
            <source>Breast Cancer Res Treat</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-72</page-range>
            <pub-id pub-id-type="pmid">10845279</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
